Brief: Zai Lab Announces Positive Topline Phase 3 Results For Bemarituzumab In Fibroblast Growth Factor Receptor 2B (FGFR2b) Positive First-Line Gastric Cancer
June 30 (Reuters) - Zai Lab Ltd 9688.HK: ZAI LAB ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2B (FGFR2B) POSITIVE FIRST-LINE GASTRIC CANCER ZAI LAB LTD - PHASE 3 TRIAL MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL ZAI LAB LTD - COMMON ADVERSE EVENTS INCLUDE REDUCED VISUAL ACUITY, ANAEMIA, NEUTROPENIA ZAI LAB LTD - BEMARITUZUMAB PLUS CHEMOTHERAPY IMPROVES OVERALL SURVIVAL IN FGFR2B-POSITIVE GASTRIC CANCER Source text: ID:nBw9MDLvJa Further company coverage: 9688.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows